-
Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit
Time of Update: 2022-05-02
For this cooperation, the industry believes that, in addition to speeding up the integrated competitiveness of the research and development, production and sales of Kangfang biopharmaceuticals, it is also a manifestation of domestic innovative pharmaceutical companies strengthening the independent controllability of the supply chain and domestic substitution .
-
Intellia and Regeneron Announce Latest Phase 1 Clinical Trial Data of NTLA-2001
Time of Update: 2022-05-02
The results showed that all doses administered were well tolerated, with mean 86% and 93% reductions in serum levels of the target protein in the two highest dose groups, respectively .
-
Since 2022, a large number of pharmaceutical companies have joined the team to sell assets
Time of Update: 2022-05-02
For example, in mid-February, some industry sources said that Sandoz, a generic drug company owned by Novartis, may be sold to private equity firms Blackstone Group and Carlyle Group for $25 billion.
-
349 medicines will be transferred out of medical insurance
Time of Update: 2022-05-02
com, excluding the varieties that have been included in the national medical insurance, there are 41 varieties supplemented by 15 or more provinces and cities (12 of which are 20 or more), of which 35 are chemical drugs and 6 are Chinese patent medicines.
-
The transformation of the pharmacy industry is accelerating, and the development of diversification and specialization has become the general trend
Time of Update: 2022-05-02
Enterprises have been determined to carry out the pilot work of comprehensive reform of large chain convenience stores operating only Class B non-prescription drugs in the whole province .
As early as 2020, it issued an announcement stating that the company and its wholly-owned subsidiary Hainan Hongxiang Yixintang Pharmaceutical Chain Co.
-
More than 900 companies were investigated, and 2 pharmaceutical machine companies received attention from more than 20 institutions
Time of Update: 2022-05-02
Among them, in view of the company's future business growth, Chutian Technology said that three years ago, the company has been deploying import substitution in the high-end market of vaccine products, and product performance and quality have been able to meet the needs of high-end customers .
-
In the field of first-in-class, a large number of local pharmaceutical companies are actively deploying
Time of Update: 2022-05-02
In recent years, with the advancement of policies such as the reform of the drug review and approval system and the drug marketing authorization holder system, China's biopharmaceutical industry has continued to grow and develop, and has inspired a large number of local pharmaceutical companies to increase investment in research and development, improve innovation strength, and gradually change from Generic drugs such as me-too are upgraded to First-in-class innovative drugs .
-
Chengdu Beite Calcium Gluconate Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-05-02
Data source: Minet database, CDE On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review .
-
The transformation of pharmaceutical companies is accelerating and forcing the upgrading of production equipment, and pharmaceutical machine companies need to fight a "cooperation war"
Time of Update: 2022-05-02
For example, last year, Hongdou Group's anti-tumor high-end complex preparation smart factory project with a total investment of 520 million yuan has officially started .
There is also a smart medical equipment manufacturing project invested by a pharmaceutical machine company of 1 billion yuan.
-
Global Sales Revenue and Competitive Outlook of ADC Drugs in 2021
Time of Update: 2022-05-02
In addition, the clinical study data (DESTINY-Breast04) of Enhertu in the third-line treatment of breast cancer patients with low expression of Her2 will also be announced and submitted for marketing application in 2022 .
-
Analyzing the advantages of the "Belt and Road" and talking about the possibility of generic drugs going overseas
Time of Update: 2022-05-02
On the other hand, with the encouragement and promotion of the "One Belt, One Road" policy, pharmaceutical companies will no longer export generic drugs to countries along the route alone, which can effectively reduce risks and improve the possibility of success and profitability .
-
Shuanghe Pharmaceutical, a wholly-owned subsidiary of China Resources Double Crane, passed the CDE technical review for the API of ticagrelor
Time of Update: 2022-05-02
On February 23, China Resources Double-Crane announced that its wholly-owned subsidiary, Double-Crane Pharmaceutical Co. , Ltd. , passed the technical review of the Drug Evaluation Center of the State
-
WuXi Junuo: The marketing application for the second indication of CD19 CAR-T was accepted by the State Food and Drug Administration
Time of Update: 2022-05-02
This is WuXi Junuo's second marketing authorization application for Benoda® and is expected to be the first cell therapy product approved in China for the treatment of patients with r/r FL .
-
The centralized procurement of dental implants is already in the air, will the price be greatly reduced in the future?
Time of Update: 2022-05-02
After the National Medical Insurance Bureau clarified the centralized procurement of dental implants, the market has also expressed concern about the attitude of related dental companies .
-
Within 1 day, the executives of China Resources Sanjiu and other two pharmaceutical companies changed
Time of Update: 2022-05-02
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries .
-
Pharmaceutical companies are in hot pursuit of innovation and R&D, with more than 20 new applications for Category 1 drug trials added within a week
Time of Update: 2022-05-02
Coincidentally, the marketing application of the new anti-tumor drug MET inhibitor Gumetinib, jointly developed by Haihe Pharmaceuticals and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has also been accepted by the State Food and Drug Administration and is being announced for priority review .
-
More than 240 pharmaceutical companies have disclosed performance forecasts, with dazzling net profits concentrated in the fields of vaccines and testing
Time of Update: 2022-05-02
. In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
-
Under the intensified competition in the generic drug market, improved drugs have become a new hot spot for research and development
Time of Update: 2022-05-02
In general, under the background of accelerated innovation and development of pharmaceutical companies, improved new drugs with obvious clinical advantages and less risk will usher in a "R&D outlet" with policy support .
-
Qilu, China Resources... siege 600 million painkillers!
Time of Update: 2022-05-02
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical Co.
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical Co.
-
In 2022, there will be many good news in the field of double-antibody drugs, and the market will explode
Time of Update: 2022-05-02
On January 5, Pharmaco announced that its self-developed Kadeninumab (AK104) combined with AK112 double antibody phase Ib/II clinical trial application was approved by NMPA, with or without chemotherapy for the treatment of advanced non-small cell lung cancer.
